Adam Bhatt

Adam Bhatt specializes in systemic therapy for advanced and radioiodine-refractory differentiated thyroid cancer. His clinical research has characterized the efficacy and toxicity management of multikinase inhibitors lenvatinib and sorafenib in radioiodine-refractory thyroid cancer, including long-term outcomes data from clinical trial and real-world populations. He has developed strategies for managing the unique toxicity profiles of multikinase inhibitors in thyroid cancer patients including hypertension, hand-foot syndrome, and hypothyroidism. His work on sequential therapies and combinations with immunotherapy for advanced thyroid cancer aims to improve long-term outcomes in this setting.